The Global Health Body Raises Warning Over Acute Scarcity of Obesity Medications
Less than a tenth of individuals who could benefit from obesity jabs such as Wegovy are able to get them, caution the WHO as it releases its initial recommendations on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging broader and more equitable availability to this class of drugs.
Per estimates, more than two billion are projected to be obese by 2030 if no action is taken.
"The new guidelines recognises that excess weight is a chronic disease that can be addressed with thorough and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major hurdles to broad access to the injections that can help people shift considerable body mass, notes the organization.
Skinny Jab Supply Crisis
Even under the present best projected case, the production of GLP-1 therapies might only reach about 100 million people – less than 10% of eligible patients, per the health organization.
The guideline urges nations and manufacturers to expand access, via approaches like licensing agreements.
Exclusive production rights on semaglutide – the core component of a leading brand – is scheduled to end in several nations in 2026.
The Way Weight-Loss Jabs Function
GLP-1 drugs mimick a natural hormone to slow digestion, reduce hunger and boost feelings of fullness so people consume fewer calories.
People usually see weight reduction in the initial weeks of commencing the regular doses.
Evidence indicates users may see weight return after a year of halting the medication, as their usual food cravings resume.
Being carrying excess weight elevates your risk for developing medical conditions, like diabetes, heart disease, brain attack, and specific cancers.
Obesity concerns people in every country and was responsible for over three and a half million deaths worldwide in 2024, according to the health agency.
